STOCKS TELEGRAPH

Tag: NovaBay Pharmaceuticals

  • NovaBay Pharmaceuticals Surpasses Resistance in After-Market Trading

    NovaBay Pharmaceuticals, Inc. (NYSE: NBY), a biopharmaceutical company specializing in eyecare, skincare, and wound care products, experiences an astonishing after-market price surge.

    While the stock remained stable throughout the day, it soared an impressive 42% after hours. This unexpected spike captures attention and raises speculation about the driving factors behind NovaBay Pharmaceuticals’ remarkable after-market performance.

    NBY Bulls Optimistic After Resistance Line Breakthrough

    NovaBay Pharmaceuticals, Inc. (NBY) witnessed a remarkable surge in its stock price during after-hours trading, climbing from $0.70 to over $1. Traders are closely monitoring resistance levels, with the potential for the stock to reach $1.30, $1.70, and possibly even $3.30 when the market opens.

    While some traders may cash out to recover losses, others believe this is just the beginning of a larger upward movement, potentially yielding over 400% gains. Speculation is growing about an upcoming announcement that could unveil significant positive developments, with expectations high for the following week.

    Positive NovaBay Pharmaceuticals Results

    NBY experienced a price surge due to a positive quarterly report. The company saw increased revenue from its Avenova eyecare products, driven by higher sales and growing interest. They also benefited from cost reductions in sales and marketing through digital optimization, leading to a margin improvement of 62%, compared to the prior year’s 55%.

    NBY has been focusing on expanding its product portfolio and recently introduced new branded products, including a solution for relieving psoriasis symptoms. In the wound care segment, a significant order was shipped to their partner in China. The company expects the recent financing and strong sales to contribute to its goal of achieving profitability.

    Conclusion

    NovaBay Pharmaceuticals experiences a staggering 42% after-market price jump, sparking speculation about upcoming positive developments. Traders monitor resistance levels, anticipating potential gains of up to $3.30. NBY’s positive quarterly report reveals increased revenue and cost reductions, supporting the company’s goal of achieving profitability.

  • Do NovaBay (NBY) Fit In A Value Investing Philosophy?

    NovaBay Pharmaceuticals Inc. (NBY) shares were rising 15.25% to trade at $0.34 in pre-market at last check. NovaBay (NBY) stock gained 0.68% to close Thursday’s session at $0.295. The stock volume remained 0.62 million shares, which was lower than the average daily volume of 0.98 million shares within the past 50 days. NBY shares have fallen by -67.69% over the last 12 months, and they have moved down by -5.63% in the past week.

    Over the past three months, the NovaBay (NBY) stock has lost -44.90%, while over the past six months, it has shed -55.75%. Further, NovaBay has a current market of $13.63 million and its outstanding shares stood at 44.92 million. As the NBY stock is surging pre-market in absence of current news, we can then point to recent developments to provide a more thorough understanding of NBY.

    How did things go as of late at NBY?

    NovaBay (NBY) creates and sells experimentally made and clinically demonstrated buyer items for the eyecare and skincare markets. Avenova is the country’s most endorsed antimicrobial cover and lash splash for blepharitis and dry eye. In November 2021, NovaBay obtained DERMAdoctor, LLC, an organization offering in excess of 30 dermatologist-created skincare items sold through conventional homegrown retailers, advanced magnificence channels and worldwide merchants.

    NovaBay (NBY) as of late reported its obligation to give 2.5 million KN95 protective masks to schools, youth gatherings and other magnanimous associations.

    • NBY has been selling masks all through the pandemic, at this point during this crucial time with the profoundly infectious Omicron variation spreading so quickly, the organization has chosen to give covers also.
    • These defensive masks are great, having particulate filtration productivity of 95% or above, and offer preferable security over a fabric mask.
    • A few associations have as of now been distinguished for donation; in any case, NovaBay (NBY) is as yet inviting new demands.
    • For qualified 501(c) (3) altruistic associations keen on getting a gift of KN95 masks, NBY mentioned to contact Bree Harrison at bharrison@novabay.com.
    • NBY encouraged that the donation may be made to charity associations and schools.

    NBY’s further plans:

    NovaBay (NBY) likewise last week declared that its Special Meeting of Stockholders hung on December 17, 2021, as deferred to and reconvened on January 14, 2022, has been additionally dismissed until January 31, 2022 at 11:00 a.m. Pacific time. To give investors extra an ideal opportunity to decide on Proposal Two, which is a proposition to endorse an alteration to the NovaBay Amended and Restated Certificate of Incorporation to impact an increment in approved normal stock from 100,000,000 offers to 150,000,000 shares.

  • NovaBay Pharmaceuticals, Inc. (NBY) stock Advances Further After Hours. Why?

    NovaBay Pharmaceuticals, Inc. (NBY) stock Advances Further After Hours. Why?

    NovaBay Pharmaceuticals, Inc. (NBY) stock gained a further 6.29% in the after-hours on December 29. The stock has been bullish with no new announcement from the company while it announced a special meeting of stockholders on December 21.

    During the normal trading session, the stock fluctuated between a high of $0.45 and a low of $0.37. After closing the session with a gain of 2.15% at $0.40, NBY gained further after hours. In the after-hours session, the stock went up by 6.29% at $0.43 with 1.95 million shares exchanging.

    Currently, the 44.96 million outstanding shares of the company trade at a market capitalization of $17.76 million.

    NBY’s Special Meeting of Stockholders

    On December 21, NBY announced the adjournment of its Special Meeting of Stockholders until January 14, 2022. The reason for this adjournment is additional time provision to stockholders for voting on Proposal Two. This is a proposal for the approval of an amendment to the NovaBay Amended and Restated Certificate of Incorporation. Moreover, this amendment will increase the authorized common stock to 150,000,000 shares from 100,000,000.

    As per the meeting, 83.5% of the votes were in favor of Proposal Two, but it was still less than 50% of all outstanding common stock shares. For Proposal Two to be officially approved, the vote of more than 50% of all outstanding shares is required to be in favor. Moreover, the rest of the proposals presented in the meeting only need majority votes from the present shareholders in the quorum.

    Other Recent News

    On December 13, NBY announced that DERMAdoctor’s balm was awarded Seal of AcceptanceTM by NEA. The National Eczema Association awarded the seal to its Clam Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm. Moreover, the balm is part of the Calm Cool + Corrected line of skin solutions of DERMAdoctor. Furthermore, the formula is suitable for all ages including peads for head-to-toe use.

    NBY’s Q3 Financial Highlights

    NovaBay Pharmaceuticals announced its financial results for the third quarter of 2021, on November 11. In the third quarter of 2021, the net product revenue of NBY was $1.8 million against $2.2 million in the year-ago quarter.

    Moreover, the company incurred a net loss of $2.3 million in the third quarter of 2021, against $3.2 million in Q3 of 2020. Consequently, the net loss per share was $0.05 and $0.08 in the third quarter of 2021 and 2020, respectively.

  • NovaBay Pharmaceuticals, Inc. (NBY) Stock Surges Following Announcement of Partnership with ImprimisRx

    NovaBay Pharmaceuticals, Inc. (NBY) Stock Surges Following Announcement of Partnership with ImprimisRx

    NovaBay Pharmaceuticals, Inc. (NBY) stock prices surged by 13.0835% some time after market trading commenced on July 19th, 2021, bringing the price per share up to USD$0.6517 early on in the trading day.

    Partnership with ImprimisRx

    July 19th, 2021 saw the company announce its partnership with ImprimisRx, leading ophthalmological pharmaceutical businesses in the United States. The partnership will facilitate the proliferation of Avenova, driven by the widespread promotion of prescription treatment. ImpromisRx will provide NBY with national sales, marketing, and distribution support for the FDA-cleared treatment, which comes in 40 ml bottles as a 0.01% hypochlorous acid. The treatment has been clinically proven to be effective in the management of numerous chronic eye conditions as an antimicrobial lid and lash solution.

    About ImprimixRx

    The partnering company has a proven track record of successfully commercializing high-quality products through its extensive consumer base of thousands of ophthalmologists and optometrists. This position itself superbly to partner up with NBY to expand the reach of Avenova. With its cutting-edge model, ImprimisRx has streamlined the ordering and delivery of products by making the pharmaceutical value chain leaner.

    Details of the Agreement

    As per the agreement, the expansion of Avenova within the prescription channel via cost-effective means has been made possible. This will be done by facilitating the engagement of ophthalmologists and optometrists, enhancing the accessibility of Avenova to unprecedented levels. The compelling addition of the treatment to the company’s ophthalmic product portfolio is set to support its long-standing commitment to its loyal customer base.

    Scope of Avenova

    The treatment caters to a massive dry eye market that is rapidly growing, with the current indication of as many as 30 million Americans reporting suffering from chronic eye conditions, such as blepharitis and meibomian gland dysfunction. The unique treatment is the only lid and lash spray that is suitable for everyday use, having been formulated with NovaBay’s patented pure hypochlorous acid. Avenova is typically prescribed before and after cataract and Lasik procedures by ohthalmologists and optometrists, consolidating it as a complementary treatment for many of the partnering company’s existing product line.

    Future Outlook for NBY

    Armed with the expansive scope of its new strategic partnership, NBY is poised to capitalize on the added opportunities in front of it. The company is keen to usher in further growth by allocating resources towards the expansion and consolidation of the market footprint of Avenova. Investors are confident in management’s ability to leverage their resources to drive increases in shareholder value.